Retatrutide: The Next-Generation Triple Agonist That Could Change Weight Loss

When tirzepatide launched and showed 20-22% weight loss in clinical trials, many clinicians called it revolutionary — and they were right. Semaglutide had already redefined what was possible with 15% weight loss, and tirzepatide pushed that ceiling even higher. But Eli Lilly's research team didn't stop there. Retatrutide, currently known by its compound designation LY3437943, takes the dual-agonism approach of tirzepatide and adds a third receptor target — glucagon — creating what scientists call a "triple agonist" with Phase 2 results that have genuinely surprised researchers.

Section 1: What Is Retatrutide?

Retatrutide is a once-weekly injectable peptide molecule developed by Eli Lilly and Company. Its compound designation is LY3437943. The drug is designed to simultaneously bind to and activate three distinct hormone receptors in the body: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GcgR). This triple receptor activation is the fundamental distinction between retatrutide and tirzepatide, which activates only the first two.

The idea of targeting glucagon receptors for weight loss might seem counterintuitive, since glucagon is primarily known for raising blood sugar — the opposite of what you want in a diabetes or obesity treatment. However, glucagon also has a powerful effect on energy expenditure. By activating glucagon receptors in adipose (fat) tissue and the liver, retatrutide is designed to increase metabolic rate and enhance fat oxidation, accelerating the caloric deficit beyond what appetite suppression alone can achieve. The GIP and GLP-1 components help offset the blood-sugar-raising effect of glucagon, maintaining glycemic safety while capturing glucagon's fat-burning benefits.

Section 2: How Triple Agonism Works — The Science Behind the Results

To understand why retatrutide's results are so impressive, you need to understand what each receptor target does and how the three mechanisms compound on each other.

GIP (Glucose-Dependent Insulinotropic Polypeptide): GIP is an incretin hormone secreted by the small intestine in response to food intake. It stimulates insulin secretion in a glucose-dependent manner (meaning it only releases insulin when blood sugar is elevated, reducing hypoglycemia risk), enhances fat storage in adipocytes, and may have direct effects on appetite. In the brain, GIP receptors appear to modulate reward signals related to food consumption. Tirzepatide's dual GIP/GLP-1 mechanism has already demonstrated superiority over GLP-1 agonism alone, and retatrutide retains this full GIP component.

GLP-1 (Glucagon-Like Peptide-1): The most well-understood target in the group, GLP-1 receptors are activated by semaglutide, tirzepatide, and all current approved GLP-1 medications. GLP-1 receptor agonism suppresses appetite through central nervous system effects (particularly in the hypothalamus), slows gastric emptying (helping patients feel full longer), reduces glucagon secretion in the pancreas (lowering blood sugar), and stimulates insulin production. These combined effects produce the appetite suppression and blood sugar improvements that have made GLP-1 medications so effective.

Glucagon: This is the novel addition. Glucagon, produced by alpha cells in the pancreas, traditionally raises blood sugar by triggering liver glycogen breakdown. But glucagon also activates pathways in the liver (increasing hepatic fat oxidation) and in adipose tissue (increasing lipolysis — the breakdown of stored fat). Animal studies showed that glucagon receptor agonism could meaningfully increase resting metabolic rate. The challenge has always been the blood-sugar-raising effect. Retatrutide's simultaneous GLP-1 activation counteracts this concern, allowing the metabolic rate boost without clinically significant hyperglycemia.

The synergy between these three mechanisms may explain why Phase 2 data exceeded expectations. Retatrutide is essentially generating a caloric deficit through three simultaneous pathways: eating less (GLP-1/GIP appetite suppression), absorbing energy more slowly (GLP-1 gastric emptying delay), and burning more calories at rest (glucagon-mediated metabolic rate increase).

Section 3: Phase 2 Results — What the Data Shows

The Phase 2 results for retatrutide, published in The New England Journal of Medicine in 2023, genuinely surprised the research community. The randomized, double-blind, placebo-controlled trial enrolled participants with obesity (BMI ≥30) or overweight (BMI 27-30 with at least one weight-related comorbidity) and followed them for 48 weeks.

An important caveat: Phase 2 results don't always predict Phase 3 outcomes. Phase 2 trials tend to use smaller, more selected patient populations, and the treatment duration (48 weeks) was shorter than the 72-week SURMOUNT trials that established tirzepatide's Phase 3 efficacy. The ongoing TRIUMPH Phase 3 program will provide a definitive picture of retatrutide's efficacy in a broader, more diverse patient population over longer timeframes.

The Phase 2 data also showed meaningful improvements in cardiometabolic markers: significant reductions in waist circumference, blood pressure, triglycerides, and HbA1c in participants with pre-diabetes or T2D. These secondary findings support retatrutide's potential for broad cardiometabolic benefit, not just weight reduction.

Section 4: The TRIUMPH Phase 3 Program — Current Status

Eli Lilly's Phase 3 program for retatrutide is called TRIUMPH — a nod to the drug's ambitious goals. The program encompasses multiple trials evaluating retatrutide in different populations and for different endpoints.

The core obesity trials (TRIUMPH-1 and TRIUMPH-2) are enrolling participants with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. These trials are expected to run for 72-96 weeks to match the duration of tirzepatide's SURMOUNT program. Additional trials are evaluating retatrutide specifically in patients with type 2 diabetes, and a cardiovascular outcomes trial is planned — a requirement Lilly will likely need to meet for full FDA approval.

As of early 2026, the TRIUMPH trials are enrolling and the primary completion dates fall in the 2025-2026 window for some studies. After trial completion, Eli Lilly would need to compile and submit an NDA (New Drug Application) to the FDA — a process that itself takes several months to a year to prepare. FDA review after submission typically takes 12-18 months under standard review, or 6-8 months under Priority Review if granted.

Section 5: Side Effect Profile — What Phase 2 Revealed

The safety and tolerability profile of retatrutide in Phase 2 was broadly similar to other GLP-1 medications, with some nuances worth understanding.

Gastrointestinal side effects were the most common adverse events, consistent with the GLP-1 component of the drug. Nausea was reported by a meaningful proportion of participants, particularly during the dose escalation period. Vomiting and diarrhea were also reported. These effects were generally mild to moderate in severity, dose-dependent, and diminished over time as participants' bodies adapted to the medication. The dose escalation schedule for retatrutide in Phase 2 was gradual — starting at 2mg and increasing through 4mg, 8mg, and 12mg over several months — specifically to minimize GI side effects.

The glucagon component raised early questions about whether retatrutide might cause more nausea than tirzepatide due to the additional glucagon receptor activity. Phase 2 data suggested that early nausea may indeed be somewhat more pronounced than with tirzepatide, though this was manageable with the slow dose escalation protocol and similar in intensity to the early weeks of semaglutide therapy.

Notably, the concerns associated with glucagon — primarily hyperglycemia — did not materialize as a clinical problem. The simultaneous GLP-1 agonism effectively counterbalanced glucagon's blood sugar effects. Hypoglycemia was rare and mild. Heart rate increases, similar to those seen with other GLP-1 medications, were observed but generally tolerable.

Like all GLP-1 medications, retatrutide carries a boxed warning regarding a potential risk of thyroid C-cell tumors based on animal studies. This risk has not been observed in humans with existing GLP-1 medications, but the class warning applies to all new drugs in this category until human data conclusively rule it out.

Section 6: Retatrutide vs Tirzepatide vs Semaglutide

For patients currently considering their options — or those who are on treatment and wondering if they should wait — understanding how retatrutide compares to available medications is critical.

The progression is logical: each generation of drug adds another receptor target and achieves greater weight loss. But the incremental gains are narrowing — from semaglutide to tirzepatide was a 5-7 percentage point improvement; from tirzepatide to retatrutide (if Phase 3 confirms Phase 2 results) may be an additional 2-4 percentage points. The question for patients and payers will be whether that incremental improvement justifies the wait, the potential cost premium, and any additional side effect burden.

For a current comparison of approved options, see our tirzepatide vs semaglutide comparison and our best GLP-1 for weight loss guide.

Section 7: The Bigger Picture — Retatrutide, Orforglipron, and the Future of Obesity Medicine

Retatrutide exists within a broader pipeline revolution at Eli Lilly and across the pharmaceutical industry. Understanding the full landscape helps contextualize where this drug fits.

Orforglipron is Eli Lilly's daily oral GLP-1 agonist — a small molecule pill rather than a peptide injection. Phase 2 data showed approximately 14-15% weight loss, similar to injectable semaglutide, which would be remarkable for an oral medication. If approved, orforglipron would address the injection barrier that prevents some patients from accessing GLP-1 therapy. Phase 3 trials are underway, with potential approval in a similar timeframe to retatrutide. These drugs serve very different patient segments: retatrutide targets those who want maximum efficacy (and are comfortable with injections), while orforglipron targets those for whom injection-free treatment is a priority.

CagriSema (Novo Nordisk) is another ambitious next-generation candidate — a combination of semaglutide with cagrilintide (an amylin analog). Phase 3 data has shown weight loss approaching 23-25%, putting it in the same range as retatrutide. Novo Nordisk and Eli Lilly are essentially in a race to bring the next generation of weight loss drugs to market, which is excellent news for patients and for competition on pricing.

The broader implication: by the late 2020s, patients may have access to multiple weight loss medications achieving 25%+ body weight reduction — approaching or exceeding bariatric surgery outcomes for many patients, without the surgical risks and recovery. This is a genuinely transformational moment in obesity medicine.

For patients currently seeking treatment, the most important message is: don't wait. The medications available today — semaglutide and tirzepatide — are already life-changing. Explore your current options through our treatments page and learn how Trimi works to get you started quickly and affordably. You can always reassess when new options become available.

For long-term safety context on currently available GLP-1 medications, see our GLP-1 long-term safety guide.